Exploring the Impact of Diurnal Variation on Coagulation Function in Patients Undering Tumor Surgery

September 20, 2026 updated by: Jun Zhang, Fudan University

Studies have shown that compared to the evening, the platelet adhension and aggregation functions of normal individuals are stronger in the morning, reaching peak at around 8AM or 9AM. Fibrinolysis is weakest at 7-11AM, and most active at midnight. previous studies have been contradictory regarding the rhythm of plasmin. Some show the level of plasmin complexes is highest at night, while some show higher in the morning and some show there is no rhythmicity.

Since patients with tumors often have a hypercoagulable state, we try to find a method to assess whether cancer patients have the same circadian with heathy individuals. And whether the surgery time(in the morning or in the evening) will affect the tumor patients' postoperative coagulation function

Study Overview

Status

Enrolling by invitation

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200333
        • Fudan University Shanghai Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The subjects of the study were 83 patients scheduled for gastrointestinal tumor surgery under general anesthesia.

Description

Inclusion Criteria:

  • 1) Patients who signed the informed consent form and were willing to complete the study according to the protocol.

    2) Patients who underwent surgical treatment for digestive tract tumors. 3) The operation start time was from 8:00 to 9:00 in the morning and from 19:00 to 20:00 in the evening.

    4) ASA grade I-II. 5) Age ranging from 20 to 70 years old.

Exclusion Criteria:

  • 1) History of thrombosis-related diseases 2) Use of anticoagulants (excluding aspirin, which should be discontinued for one week) 3) Hb < 90g/dL 4) Diabetic patients [14] 5) Patients admitted to ICU after surgery 10) Those who have participated in other clinical trials or refused to join the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
morning surgery group
night surgery group

no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
preoperative TEG values
Time Frame: one day
one day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

July 30, 2027

Study Registration Dates

First Submitted

September 20, 2026

First Submitted That Met QC Criteria

September 20, 2026

First Posted (Actual)

September 25, 2026

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 20, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • FudanU25.4.21

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe